Experienced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Experienced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Kaiser Permanente
Kaiser Permanente Los Angeles Medical Center - Pediatrics Department
4950 W Sunset Blvd, 
Los Angeles, CA 

Overview

Robert Cooper is an Oncologist and a Pediatrics provider in Los Angeles, California. Dr. Cooper is rated as an Experienced provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Leukemia, Hepatoblastoma, Acute Lymphoblastic Leukemia (ALL), Ependymoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 66 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Oncology
Pediatrics
Licenses
Pediatric Hematology-Oncology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Kaiser Permanente Los Angeles Medical Center - Pediatrics Department
4950 W Sunset Blvd, Los Angeles, CA 90027

Additional Areas of Focus

Dr. Cooper has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


66 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
View 49 Less Clinical Trials
Similar Doctors
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Oncology | Hematology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Oncology | Hematology
390 North Pacific Coast Highway, Suite 1020, 
El Segundo, CA 
 (13.9 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Frank Mori is a Hematologist and an Oncologist in El Segundo, California. Dr. Mori is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia. Dr. Mori is currently accepting new patients.

Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Oncology | Hematology Oncology
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Oncology | Hematology Oncology
50 Alessandro Place, Suite 310, 
Pasadena, CA 
 (8.7 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Jason Ho is a Hematologist Oncology specialist and an Oncologist in Pasadena, California. Dr. Ho is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Ho is currently accepting new patients.

Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Advanced in Alpha Thalassemia X-Linked Intellectual Disability Syndrome
Camarillo, CA 
 (45.6 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Chirag Dalsania is a Hematologist in Camarillo, California. Dr. Dalsania is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia X-Linked Intellectual Disability Syndrome. His top areas of expertise are Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, and Polycythemia Vera. Dr. Dalsania is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cooper's expertise for a condition
ConditionClose
      View All 21 Advanced Conditions
      View All 38 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile